LINCOLN PHARMACEUTICALS
|
The Current P/E Ratio of LINCOLN PHARMACEUTICALS is 13.86.
Share Price | ₹570.7 | Jun 18,2025 |
Market Cap | ₹1,141.3 Cr | |
Earnings-TTM | ₹82.3 Cr | TTM-Consolidated Results |
Price/Earnings | 13.86x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of LINCOLN PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,141.3 Cr] as on Jun 18,2025
(/) Earnings [ ₹82.3 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 13.86x ]
Thus, for LINCOLN PHARMACEUTICALS , the investors are currently willing to pay 13.86 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of LINCOLN PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of LINCOLN PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of LINCOLN PHARMACEUTICALS
PE Ratio Performance Analysis for LINCOLN PHARMACEUTICALS
- LINCOLN PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 8.66x.
- LINCOLN PHARMACEUTICALS 's operated at median p/e ratio of 8.98x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, LINCOLN PHARMACEUTICALS 's p/e ratio peaked in Mar2024 at 12.57x.
- LINCOLN PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2020 of 5.2x.
How does LINCOLN PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
LINCOLN PHARMACEUTICALS | 82.35 | 13.86 | 1,141.3 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 10,980.10 | 36.00 | 395,326.0 |
DIVIS LABORATORIES LTD | 2,191.00 | 79.22 | 173,562.0 |
CIPLA LTD | 5,291.05 | 22.87 | 121,023.0 |
TORRENT PHARMACEUTICALS LTD | 1,911.00 | 57.14 | 109,204.0 |
DR REDDYS LABORATORIES LTD | 5,703.50 | 19.21 | 109,558.0 |
MANKIND PHARMA LTD | 2,003.22 | 48.50 | 97,164.6 |
ZYDUS LIFESCIENCES LTD | 4,614.80 | 20.88 | 96,377.1 |
LUPIN LTD | 3,306.26 | 26.99 | 89,224.6 |
AUROBINDO PHARMA LTD | 3,515.26 | 18.29 | 64,297.6 |
ABBOTT INDIA LTD | 1,414.44 | 47.33 | 66,951.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs LINCOLN PHARMACEUTICALS 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 13.86x |
Max industry PE | 79.22x |
Median industry PE | 26.99x |
Average industry PE | 35.48x |
You may also like the below Video Courses